Disc Medicine to pursue traditional U.S. approval after FDA rejects new fast-track route
Feb 17 (Reuters) – Disc Medicine said ‌on Tuesday it ‌will pursue a traditional ​U.S. approval pathway for…
Appeasing Trump is a strategic mistake. Luxon should know better.
David Seymour slipped up on Herald Now. Ryan Bridge caught Seymour admitting that a critical minerals deal with…
NRx submits 70,000-patient ketamine data to US FDA
NRx Pharmaceuticals (Nasdaq: NRXP) will submit real-world evidence from over 70,000 patients treated with intravenous ketamine…